Can a Two-Drug punch wake up 'Cold' tumors?

NCT ID NCT05000294

First seen Jun 26, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This study tests whether adding tivozanib (a drug that targets blood vessel growth) to atezolizumab (an immunotherapy) can help the immune system attack cancers that normally resist immunotherapy. The trial includes people with several cancer types like bile duct, pancreatic, prostate, and ovarian cancer. Researchers will check if the combination shrinks tumors and how long it keeps them from growing.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance

Atezolizumab (Tecentriq) and tivozanib (Fotivda)

What this could lead to

If it works, this could offer a new treatment option for several hard-to-treat cancers that don't respond to immunotherapy alone.

What could go wrong

This is an early-phase trial with only 29 participants, so results may not apply broadly. The combination may cause side effects like high blood pressure or immune-related reactions.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for BREAST CANCER are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

bile duct cancer bile duct neoplasm breast cancer breast carcinoma breast neoplasm gallbladder cancer gallbladder neoplasm neuroendocrine carcinoma neuroendocrine neoplasm ovarian cancer pancreatic adenocarcinoma prostate cancer sarcoma soft tissue sarcoma vulva cancer

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Contacts and locations

Study contacts

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

Locations

  • University of Florida

    RECRUITING

    Gainesville, Florida, 32608, United States

    Contact Phone: •••-•••-•••• Email: •••••@•••••

    Contact